Product Information
| MW (kDa) | 24 |
| Purity | >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mLCN2 All lots are greater than 98% pure. |
| Endotoxin | Less than 0.01 ng endotoxin/1 μg mLCN2. |
| Activity | The bioactivity of mLCN2 was determined in a BAF3 cell viability assay. The ED50 of each lot is between 0.5-4 µg/ml. |
| Molecular Formula | Recombinant mLCN2 contains no "tags" and the nonglycosylated protein has a calculated MW of 20,874. DTT-reduced and non-reduced proteins migrate as 24 kDa polypeptides. |
Recombinant mouse LCN2 (mLCN2) Gln21-Asn200 (Accession #P11672) was expressed in human 293 cells at Cell Signaling Technology.
Lipocalin-2, a member of the lipocalin family of proteins, was originally identified as a gelatinase-associated component of neutrophil secretory granules (1). Lipocalin-2 is involved in innate immunity, iron homeostasis, and apoptosis. Lipocalin-2 limits bacterial growth by binding to bacterial siderophores and sequestering iron (2-4). In mammalian cells, iron-loaded lipocalin-2 binds to its receptor, 24p3R, and is internalized, thereby releasing iron and increasing the intracellular iron concentration (5). Conversely, iron-free lipocalin-2 promotes apoptosis (5). Lipocalin-2 is also expressed in adipose tissue and promotes insulin resistance in cultured mouse adipocytes (6).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
PhosphoSitePlus®